The Effectiveness of Phytotherapy in SARS-COV2(COVID-19)

Phase 1

Completed

• Conditions: a Randomized Double-blind Study; Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); PHYTOTHERAPIE
• Interventions: Drug: Quercetin

• Registration Number: NCT04851821
• Lead Sponsor: Hôpital Universitaire Sahloul

Brief Summary

Quercetin is one of the flavonoids. Quercetin as well as rutin are recognized to be among the most active of the flavonoids. It is to quercetin that several medicinal plants, including ginkgo and St. John's Wort, owe part of their therapeutic effects. Often combined with vitamin C in supplements, it improves absorption by the body and delays its elimination.

Quercetin is extracted from a variety of plant sources, including the onion peel and seeds and pods of Dimorphandra mollis, a tree in the legume family native to South America.

At present, there is no scientific data to demonstrate the effectiveness of herbal medicine, regardless of the plant, to prevent or treat COVID-19. On the other hand, some plant-based food supplements have anti-inflammatory or immunomodulatory properties that may disrupt inflammatory defense mechanisms useful in fighting infections, and in particular against COVID-19.

Detailed Description

Type of study: a randomized, double-blind study using the Quercetine in the treatment of patients with SARS COV2 (covid-19) Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America.

Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies.

History on quercetin In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins.

Study Timeline

• Study Start: 2021-01-04
• Study First Submitted: 2021-02-06
• Study First Submitted QC: 2021-04-18
• Study First Posted: 2021-04-20
• Primary Completion: 2021-05-30
• Study Completion: 2021-06-30
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-02
• Last Update Posted: 2023-01-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• all patients attending the emergency department for influenza-like illness.
• Being over 18 years old

Exclusion Criteria

• Any patient requiring admission
• Non-consenting patients

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Quercetix group	Quercetin	Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
Placebo Group	Quercetin	Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.

Primary Outcome Measures

Name	Time	Method
Number of patients	10 DAYS	Number of patients attending the emergency room

Secondary Outcome Measures

Name	Time	Method
disappearance of symptoms	10 days	Date of disappearance of symptoms present on admission
adverse reaction	10 days	Presence of an adverse reaction due to the administration of the treatment

Trial Locations

Locations (1)

Riadh Boukef; 🇹🇳 Sahloul, Sousse, Tunisia